A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Study to Evaluate the Efficacy and Safety of Zovaglutide in Adults With Overweight or Obesity.
Latest Information Update: 19 Jan 2026
At a glance
- Drugs Zovaglutide (Primary)
- Indications Obesity
- Focus Registrational; Therapeutic Use
- Acronyms HORIZON-1
- Sponsors QL Biopharmaceutical
Most Recent Events
- 23 Dec 2025 Planned number of patients changed from 620 to 744.
- 17 Nov 2025 Status changed from planning to not yet recruiting.
- 10 Nov 2025 New trial record